Engineers Gate Manager’s Astria Therapeutics ATXS Stock Holding History

Engineers Gate Manager’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,856	Closed	-$234K	–	2175
2025 Q4	$234K	Sell	17,856 -7,168	-29%	-$85.6K	﹤0.01%	1743
2025 Q3	$182K	Buy	+25,024	New	+$169K	﹤0.01%	1926
2025 Q1	–	Sell	-12,069	Closed	-$108K	–	2146
2024 Q4	$108K	Buy	+12,069	New	+$128K	﹤0.01%	1986
2024 Q3	–	Sell	-13,064	Closed	-$119K	–	2108
2024 Q2	$119K	Buy	+13,064	New	+$128K	﹤0.01%	1728
2021 Q2	–	Sell	-2,200	Closed	-$38K	–	1599
2021 Q1	$38K	Buy	+2,200	New	+$39.7K	﹤0.01%	1760

Engineers Gate Manager's ATXS Position: Q1 2026 in Review

Engineers Gate Manager sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 17,856 shares — an estimated $234K sold.

Engineers Gate Manager first reported a position in ATXS in Q1 2021 and held it in 5 quarters. The position peaked at $234K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Engineers Gate Manager reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Engineers Gate Manager sold 17,856 Astria Therapeutics shares in Q1 2026, an estimated $234K.
Engineers Gate Manager first reported a position in Astria Therapeutics in Q1 2021 and held it in 5 quarters.
Engineers Gate Manager's Astria Therapeutics position peaked at $234K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Engineers Gate Manager's 13F filing for Q1 2026, filed 15 May 2026.